The ID Consortium evaluates pathogens based on occurrence, threat severity, and treatment availability. Our lab and therapeutic access services currently focus on the following pathogens:
Bacteria
- Multidrug-resistant Clostridium difficile
- Carbapenem-resistant Enterobacteriaceae
- Multidrug-resistant Acinetobacter
- Extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs)
- Vancomycin-resistant Enterococcus (VRE)
- Multidrug-resistant Pseudomonas aeruginosa
- Methicillin-resistant Staphylococcus aureus (MRSA)
- Drug-resistant Streptococcus pneumoniae
- Vancomycin-resistant Staphylococcus aureus (VRSA)
- Mycobacterium tuberculosis
Viruses (life-threatening cases)
- Respiratory Syncytial Virus (RSV)
- Influenza
- Parainfluenza
- Cytomegalovirus (CMV)
- Adenovirus
Fungi
If you have a patient with a life threatening multi-drug resistant infection, and you do not see the pathogen listed, please contact us to discuss.
- Fluconazole-resistant Candida
- Multidrug-resistant Candida spp.
- Triazole-resistant Aspergillus spp
- Fusarium spp
- Scedosporium spp